QuidelOrtho Corporation (QDEL)

NASDAQ: QDEL · Real-Time Price · USD

10.32

-1.07 (-9.39%)

At close: May 15, 2026, 4:00 PM EDT

10.37

+0.05 (0.52%)

After-hours: May 15, 2026, 7:59 PM EDT

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014
Period Ending	Mar '26 Mar 29, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 2, 2022	Jan '21 Jan 3, 2021	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014
North America Revenue	1.41B	1.49B	1.62B
North America Revenue Growth	-5.22%	-8.08%	-13.71%
EMEA Revenue	364.30M	360.70M	335.80M
EMEA Revenue Growth	1.00%	7.41%	2.60%
China Revenue	323.20M	334.70M	325.00M
China Revenue Growth	-3.44%	2.99%	4.81%
JPAC Revenue	-	293.00M	279.40M
JPAC Revenue Growth	-	4.87%	-
Latin America Revenue	-	252.90M	222.90M
Latin America Revenue Growth	-	13.46%	-
Other Geographies Revenue	558.60M	545.90M	502.30M
Other Geographies Revenue Growth	2.33%	8.68%	3.93%
Revenue (Total)	2.66B	2.73B	2.78B
Revenue (Total) Growth	-2.67%	-1.89%	-7.17%

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014
Period Ending	Mar '26 Mar 29, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 2, 2022	Jan '21 Jan 3, 2021	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014
Labs Revenue	1.49B	1.51B	1.43B
Labs Revenue Growth	-1.32%	5.50%	0.13%
Immunohematology Revenue	553.60M	543.80M	522.00M
Immunohematology Revenue Growth	1.80%	4.18%	1.87%
Donor Screening Revenue	47.60M	52.60M	115.10M
Donor Screening Revenue Growth	-9.51%	-54.30%	-15.43%
Transfusion Medicine Revenue	601.20M	596.40M	637.10M
Transfusion Medicine Revenue Growth	0.80%	-6.39%	-1.76%
Point of Care Revenue	543.50M	601.60M	694.60M
Point of Care Revenue Growth	-9.66%	-13.39%	-22.15%
Molecular Diagnostics Revenue	26.70M	26.50M	24.00M
Molecular Diagnostics Revenue Growth	0.76%	10.42%	-24.29%
Revenue (Total)	2.66B	2.73B	2.78B
Revenue (Total) Growth	-2.67%	-1.89%	-7.17%

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014
Period Ending	Mar '26 Mar 29, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 2, 2022	Jan '21 Jan 3, 2021	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014
North America Adjusted EBITDA	742.10M	807.00M	892.10M
North America Adjusted EBITDA Growth	-8.04%	-9.54%	-12.98%
EMEA Adjusted EBITDA	86.20M	82.60M	46.50M
EMEA Adjusted EBITDA Growth	4.36%	77.63%	13.41%
China Adjusted EBITDA	132.00M	141.20M	130.50M
China Adjusted EBITDA Growth	-6.52%	8.20%	2.59%
JPAC Adjusted EBITDA	-	73.20M	69.90M
JPAC Adjusted EBITDA Growth	-	4.72%	19.49%
Latin America Adjusted EBITDA	-	78.40M	63.60M
Latin America Adjusted EBITDA Growth	-	23.27%	11.97%
Other Geographies Adjusted EBITDA	154.30M	151.60M	133.50M
Other Geographies Adjusted EBITDA Growth	1.78%	13.56%	15.78%
Corporate Adjusted EBITDA	-569.10M	-585.40M	-659.70M
Operating Income (Total)	-983.60M	-919.20M	-1.96B

Updated May 5, 2026. Data Source: Fiscal.ai.